



NASDAQ LISTED: CNCR

Loncar Cancer Immunotherapy ETF

25 Immunotherapy Leaders, One Fund

The Loncar Cancer Immunotherapy ETF trades on Nasdaq under the symbol CNCR. It is made of up a basket of companies that develop therapies to treat cancer by harnessing the body's own immune system. Immunotherapy is a transformational field within the biotechnology space that may have a foundational impact on cancer care. By developing immunotherapies that are more effective and deliver a better quality of life than currently available medicines, innovative immunotherapy companies may be making a difference for courageous patients who battle cancer. Our fund seeks to support this important work and its positive impact on society. It tracks the LCINDX index.

INDEX DETAILS

AS OF 9/30/2019

INDEX TICKER

LCINDX

INCEPTION DATE

3/18/2015

REBALANCE SCHEDULE

Semi-Annual

WEIGHTING

Equal

NUMBER OF HOLDINGS

25

LARGE CAP IMMUNOTHERAPY LEADERS

5

CLINICAL STAGE BIOTECH

20

FUND DETAILS

AS OF 9/30/2019

TICKER

CNCR

EXPENSE RATIO

0.79%

INCEPTION DATE

10/13/2015

REBALANCE FREQUENCY

Semi-Annual

PRIMARY LISTING

NASDAQ

INDEX HOLDINGS


AS OF 9/30/2019

Ticker	Name	Weight
SGEN	SEATTLE GENETICS INC	5.34%
ZYME	ZYMEWORKS INC	5.19%
YMAB	Y-MABS THERAPEUTICS INC	5.14%
AZN	ASTRAZENECA PLC	4.87%
MOR	MORPHOSYS AG	4.76%
BMJ	BRISTOL-MYERS SQUIBB CO	4.66%
XNCR	XENCOR INC	4.48%
MRK	MERCK & CO INC	4.44%
ALLO	ALLOGENE THERAPEUTICS INC	4.39%
MRNA	MODERNA INC	4.25%
BGNE	BEIGENE LTD	4.22%
GILD	GILEAD SCIENCES INC	4.12%
IOVA	IOVANCE BIOTHERAPEUTICS INC	4.05%
CRSP	CRISPR THERAPEUTICS AG	4.00%
ARGX	ARGENX SE	3.90%
REGN	REGENERON PHARMACEUTICALS INC	3.89%
FATE	FATE THERAPEUTICS INC	3.81%
MGNX	MACROGENICS INC	3.59%
ZIOP	ZIOPHARM ONCOLOGY INC	3.54%
AUTL	AUTOLUS THERAPEUTICS PLC	3.34%
BLUE	BLUEBIRD BIO INC	3.20%
DTIL	PRECISION BIOSCIENCES INC	2.90%
CLLS	CELLECTIS SA	2.86%
ATRA	ATARA BIOTHERAPEUTICS INC	2.76%
NKTR	NEKTAR THERAPEUTICS	2.31%

*Fund holdings and allocations are subject to change at any time and should not be interpreted as an offer of these securities.

INDUSTRY BREAKDOWN

AS OF 9/30/2019



Investment Rationale

Cancer immunotherapy has become an important sector in the biotechnology space and is changing the way many cancers are treated. While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system's dynamic nature and the way it can more precisely be tailored to fight a patient's disease. Some immunotherapies have exhibited uncommon results in clinical trials.

Today, many new classes of cancer immunotherapies are being developed. These include checkpoint inhibitors (which are already FDA approved for types of melanoma, lung, kidney, bladder, lymphoma, head and neck cancer), cancer vaccines, bispecific antibodies, oncolytic viruses, and chimeric antigen receptor (CAR-T) technologies. With this distinct sector focus, the fund aims to help investors capture a growth area of the biotechnology space. At the same time, it will support this method of treating cancer by providing capital to public companies that are leaders in the space.

Index Provider

Loncar Investments LLC was founded by noted independent biotech investor and analyst Brad Loncar. Mr. Loncar regularly provides his insight and analysis on this market segment to the investment community via a variety of publishing platforms. Through Loncar Investments LLC, Mr. Loncar incorporates his extensive research into biotech companies and technologies to develop indexes focused on precise investment opportunities.



LEARN MORE

ONLINE

LoncarFunds.com

EMAIL

ETF@USbank.com

PHONE

+1-800-617-0004

The Fund's investment objectives, risks, charges and expenses must be considered carefully before investing. The summary and statutory prospectuses contain this and other important information about the investment company, and it may be obtained by calling 800-617-0004. Read it carefully before investing.

Investing involves risk, including the possible loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. The Fund will invest in immunotherapy companies which are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company's valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The costs associated with developing new drugs can be significant, and the results are unpredictable. The process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained and maintained. The Fund may invest in foreign securities, which involve political, economic, currency risk, greater volatility, and differences in accounting methods. The Fund is non-diversified meaning it may concentrate its assets in fewer individual holdings than a diversified fund. Therefore, the Fund is more exposed to individual stock volatility than a diversified fund. The Fund invests in smaller companies, which may have more limited liquidity and greater volatility compared to larger companies. The Fund is not actively managed and may be affected by a general decline in market segments related to the index. The fund invests in securities included in, or representative of securities included in, the index, regardless of their investment merits. The performance of the fund may diverge from that of the Index and may experience tracking error to a greater extent than a fund that seeks to replicate an index.

The Loncar Cancer Immunotherapy ETF is distributed by Quasar Distributors, LLC. Loncar Investments is the index provider of the Fund. INDXX, LLC helps Loncar with risk management and index construction. [1019]



LONCAR
INVESTMENTS